Genvoya

Indicated For

HIV-1 infection

About This Medication

# Gilead Advancing Access Guide: Getting Genvoya at Low Cost ## What is Genvoya? Genvoya is a prescription medication used to treat HIV-1 infection. It combines four active ingredients—elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide—into a single daily tablet. If you've been prescribed Genvoya but are concerned about the cost, the Gilead Advancing Access Patient Assistance Program can help. ## Who Qualifies for This Program? The Gilead Advancing Access program is designed for patients who are: - **Uninsured or underinsured** (meaning your insurance doesn't adequately cover the medication) - **U.S. residents** living in all 50 states, Washington D.C., and U.S. territories - **Below the income limit** of 500% of the Federal Poverty Level (FPL) ### Income Eligibility Limits (2024) Your household income must not exceed these annual amounts: - **Individual:** $68,750 - **Family of 2:** $92,250 - **Family of 3:** $115,750 - **Family of 4:** $139,250 - **Family of 5:** $163,250 *Note: Income limits increase by approximately $24,000 for each additional family member. These figures are based on 500% of the Federal Poverty Level and are updated annually.* ## Insurance Requirements You may qualify if you: - Have **no health insurance** (uninsured) - Have insurance but it **doesn't cover Genvoya** - Have insurance with **high out-of-pocket costs** (co-pays, coinsurance, or deductibles) - Are waiting for insurance coverage to begin Patients with Medicare or Medicaid may also apply, though coverage rules vary by state. Contact the program directly if you're unsure. ## What Documents Do You Need? Gather these items before applying: 1. **Proof of Income:** Recent pay stubs, tax returns, or a letter from your employer 2. **Proof of Residency:** Utility bill, lease agreement, or driver's license showing your current address 3. **Valid Prescription:** A prescription for Genvoya from your healthcare provider 4. **Insurance Information:** If you have insurance, details about your coverage (policy number, deductible, etc.) ## How to Apply **Step 1: Contact the Program** - Call **(800) 226-2056** (toll-free, available Monday–Friday, 9 a.m.–6 p.m. ET) - Visit **https://www.gileadadvancingaccess.com/patient** to apply online - Request an application by mail if you prefer **Step 2: Complete Your Application** - Fill out all required information about your income, household size, and medical history - Be honest and accurate—this determines your eligibility **Step 3: Submit Supporting Documents** - Mail, fax, or upload your proof of income and residency along with your signed application - Include a copy of your Genvoya prescription **Step 4: Wait for Approval** - The program typically reviews applications within 7–14 business days - You'll be notified by phone or mail about your approval status - Once approved, medication is shipped directly to you or your pharmacy ## Timeline and What to Expect From application to receiving your medication typically takes **2–4 weeks**, depending on: - How quickly you submit all required documents - Whether the program needs additional information - Your pharmacy's processing time Once approved, you receive **free or significantly reduced-cost Genvoya**. Most patients pay little to nothing. ## Savings Card Alternative If you don't qualify for the full assistance program but have insurance, ask your doctor about Gilead's **savings card**. This card can reduce your co-pay to as low as $0–$50 per month, depending on your insurance plan. ## Annual Reauthorization Your assistance is renewed **once per year**. The program will contact you before your eligibility expires. You'll need to resubmit proof of income and residency to continue receiving free medication. ## Need Help? If you have questions or need assistance applying: - Call **(800) 226-2056** - Visit **https://www.gileadadvancingaccess.com/patient** - Ask your doctor or pharmacist for guidance Don't let cost stop you from getting the HIV treatment you need. Apply today.

Program information last verified: March 25, 2026